Wegovy maker warns of slower profits as rivals bite
Summary
The Danish company Novo Nordisk, which makes the weight-loss drug Wegovy, announced that its profits and sales will grow more slowly than expected due to competition from other weight-loss drugs. Novo Nordisk's stock fell significantly, and they are appointing Maziar Mike Doustdar as the new CEO in August.Key Facts
- Novo Nordisk's profits and sales growth predictions have been reduced due to new competing weight-loss drugs.
- The company's stock price dropped by over 20% after the announcement.
- Lars Fruergaard Jørgensen, the current CEO, is stepping down, and Maziar Mike Doustdar will become the new CEO on August 7.
- Wegovy and Ozempic are drugs made by Novo Nordisk; Wegovy is for weight loss, and Ozempic is used by people with diabetes.
- Novo Nordisk plans to use legal actions to protect against knock-off versions of semaglutide, the active ingredient in their drugs.
- Profits are now expected to increase by 10% to 16%, down from the earlier forecast of 16% to 24%.
- Sales growth predictions have been lowered to 8% to 14%, compared to the previous forecast of 13% to 21%.
- Some analysts believe Novo Nordisk was slow to target people who might pay themselves for weight-loss treatments.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.